Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma.
Reyal F, Rouzier R, Depont-Hazelzet B, Bollet MA, Pierga JY, Alran S, Salmon RJ, Fourchotte V, Vincent-Salomon A, Sastre-Garau X, Antoine M, Uzan S, Sigal-Zafrani B, De Rycke Y. Reyal F, et al. Among authors: fourchotte v. PLoS One. 2011;6(5):e20297. doi: 10.1371/journal.pone.0020297. Epub 2011 May 31. PLoS One. 2011. PMID: 21655258 Free PMC article.
Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute.
Marszalek A, Alran S, Scholl S, Fourchotte V, Plancher C, Rosty C, Meyniel JP, De Margerie V, Dorval T, De La Rochefordière A, Cottu P, Petrow P, Sastre-Garrau X, Salmon RJ. Marszalek A, et al. Among authors: fourchotte v. Int J Surg Oncol. 2010;2010:214919. doi: 10.1155/2010/214919. Epub 2010 Jul 25. Int J Surg Oncol. 2010. PMID: 22312486 Free PMC article.
Non-sentinel lymph node metastasis prediction in breast cancer with metastatic sentinel lymph node: impact of molecular subtypes classification.
Reyal F, Belichard C, Rouzier R, de Gournay E, Senechal C, Bidard FC, Pierga JY, Cottu P, Lerebours F, Kirova Y, Feron JG, Fourchotte V, Vincent-Salomon A, Guinebretiere JM, Sigal-Zafrani B, Sastre-Garau X, De Rycke Y, Coutant C. Reyal F, et al. Among authors: fourchotte v. PLoS One. 2012;7(10):e47390. doi: 10.1371/journal.pone.0047390. Epub 2012 Oct 9. PLoS One. 2012. PMID: 23056641 Free PMC article.
Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non-BRCAness high grade ovarian carcinoma.
Goundiam O, Gestraud P, Popova T, De la Motte Rouge T, Fourchotte V, Gentien D, Hupé P, Becette V, Houdayer C, Roman-Roman S, Stern MH, Sastre-Garau X. Goundiam O, et al. Among authors: fourchotte v. Int J Cancer. 2015 Oct 15;137(8):1890-900. doi: 10.1002/ijc.29568. Epub 2015 Apr 29. Int J Cancer. 2015. PMID: 25892415 Free article.
Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial.
Rouzier R, Gouy S, Selle F, Lambaudie E, Floquet A, Fourchotte V, Pomel C, Colombo PE, Kalbacher E, Martin-Francoise S, Fauvet R, Follana P, Lesoin A, Lecuru F, Ghazi Y, Dupin J, Chereau E, Zohar S, Cottu P, Joly F. Rouzier R, et al. Among authors: fourchotte v. Eur J Cancer. 2017 Jan;70:133-142. doi: 10.1016/j.ejca.2016.09.036. Epub 2016 Dec 1. Eur J Cancer. 2017. PMID: 27914243 Free article. Clinical Trial.
Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers.
Bonsang-Kitzis H, Mouttet-Boizat D, Guillot E, Feron JG, Fourchotte V, Alran S, Pierga JY, Cottu P, Lerebours F, Stevens D, Vincent-Salomon A, Sigal-Zafrani B, Campana F, Rouzier R, Reyal F. Bonsang-Kitzis H, et al. Among authors: fourchotte v. PLoS One. 2017 Feb 27;12(2):e0169962. doi: 10.1371/journal.pone.0169962. eCollection 2017. PLoS One. 2017. PMID: 28241044 Free PMC article.
79 results